Alnylam Pharmaceuticals (ALNY)
(Real Time Quote from BATS)
$144.12 USD
+0.41 (0.29%)
Updated Apr 26, 2024 09:49 AM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Detailed Estimates
EPS Estimates
Earnings Date | *BMO5/2/24 |
---|---|
Current Quarter | -0.75 |
EPS Last Quarter | -1.10 |
Last EPS Surprise | 8.33% |
ABR | 1.84 |
Earnings ESP
|
5.87% |
---|---|
Current Year | -2.46 |
Next Year | -0.36 |
EPS (TTM) | -3.56 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 420.24M | 459.78M | 1.84B | 2.23B |
# of Estimates | 11 | 10 | 11 | 11 |
High Estimate | 443.65M | 504.80M | 1.87B | 2.61B |
Low Estimate | 400.00M | 427.00M | 1.78B | 1.88B |
Year ago Sales | 319.29M | 318.75M | 1.83B | 1.84B |
Year over Year Growth Est. | 31.62% | 44.24% | 0.88% | 21.09% |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.75 | -0.72 | -2.46 | -0.36 |
# of Estimates | 7 | 7 | 7 | 7 |
Most Recent Consensus | -0.71 | -0.92 | -2.79 | -0.74 |
High Estimate | -0.36 | -0.21 | -1.95 | 2.09 |
Low Estimate | -1.44 | -1.42 | -3.27 | -1.94 |
Year ago EPS | -1.40 | -2.21 | -3.52 | -2.46 |
Year over Year Growth Est. | 46.43% | 67.42% | 30.11% | 85.07% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 1 | 1 | 2 | 2 |
Up Last 60 Days | 1 | 1 | 2 | 2 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.75 | -0.72 | -2.46 | -0.36 |
7 Days Ago | -0.75 | -0.72 | -2.46 | -0.36 |
30 Days Ago | -0.79 | -0.73 | -2.73 | -0.67 |
60 Days Ago | -0.89 | -0.86 | -3.19 | -1.01 |
90 Days Ago | -1.45 | -1.42 | -5.55 | -2.08 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.71 | -0.92 | -3.03 | -0.96 |
Zacks Consensus Estimate | -0.75 | -0.72 | -2.46 | -0.36 |
Earnings ESP | 5.87% | -27.78% | -23.32% | -162.15% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -1.10 | 1.15 | -2.21 | -1.40 | NA |
Estimate | -1.20 | -1.61 | -1.72 | -1.97 | NA |
Difference | 0.10 | 2.76 | -0.49 | 0.57 | 0.74 |
Surprise | 8.33% | 171.43% | -28.49% | 28.93% | 45.05% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more